Suits accuse retail chains of flooding Ohio with painkillers

CLEVELAND (AP) — Five retail chains flooded two Ohio counties with tens of millions of prescription painkillers through their pharmacies while taking few if any steps to stop drugs from being illegally diverted, according to updated lawsuits unsealed in U.S. District Court in Cleveland.

The counties are Lake and Trumbull in northeast Ohio. Their lawsuits made public Wednesday allege CVS, Walgreens, Rite Aid, Walmart and Giant Eagle helped fuel a national drug crisis that resulted in more than 430,000 deaths since 2000.

The counties' complaints are scheduled for trial in May 2021 before U.S. District Judge Dan Polster, who is overseeing more than 2,000 lawsuits filed by governments, tribal authorities and others in Cleveland.

Their lawsuits are the first to target retail chains as both distributors and dispensers of prescription painkillers.

Ohio's much larger Cuyahoga and Summit counties settled a lawsuit against drug manufacturers and distributors ahead of trial last November for $260 million.

A trial for claims by Cuyahoga County, which includes Cleveland, and Summit County, which includes Akron, against retail chains is scheduled for November. Pharmacies are not part of that complaint after an appeals court sided with the companies, saying Polster improperly included them.

According to the latest lawsuits, the chain's pharmacies bought more than 61 million oxycodone and hydrocodone pills, painkillers most frequently diverted and abused, in Lake County between 2006 and 2014. That is roughly 266 pills for every Lake County resident during that period. The chains' Trumbull County pharmacies received 67 million of those pills, roughly 320 pills for every resident.

“They were keenly aware of the oversupply of prescription opioids through the extensive data and information they developed and maintained as both distributors and retail sellers of opioids," the lawsuits claim.


The companies “facilitated the supply of far more opioids that could have been justified to serve a legitimate market,” the lawsuits said.

CVS spokesman Michael DeAngelis in a statement said that opioids are made and marketed by drug manufacturers, not pharmacists, and the lawsuits' use of “decades old documents without context is misleading and doesn't change the facts.”

“Pharmacists dispense opioid prescriptions written by a licensed physician for a legitimate medical need,” DeAngelis said.

Walgreens spokesman Phil Caruso referred to an earlier statement from the company that said it never manufactured or marketed opioids and delivered prescription painkillers only to its pharmacies. Pharmacists are obliged to fill prescriptions from physicians as they are written, the company said.

A spokesman for Giant Eagle declined to comment about the lawsuits on Thursday.

Walmart and Rite-Aid did not respond to requests for comment.

Should you invest $1,000 in Rite Aid right now?

Before you consider Rite Aid, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rite Aid wasn't on the list.

While Rite Aid currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
CVS Health (CVS)
5 of 5 stars
$67.18-0.2%3.96%10.40Moderate Buy$89.44
Rite Aid (RAD)
0.1749 of 5 stars
$0.00-100.0%N/A-0.04$1.00
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Search Headlines: